利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

110 条记录 (耗时 0.05 秒)

    Method for producing sterile polynucleotide based medicaments
    4.
    发明授权
    Method for producing sterile polynucleotide based medicaments 失效
    用于生产基于无菌多核苷酸的药物的方法

    公开(公告)号：US08435557B2

    公开(公告)日：2013-05-07

    申请号：US12109944

    申请日：2008-04-25

    申请人： Joel Enas ,  Andrew Geall

    发明人： Joel Enas ,  Andrew Geall

    IPC分类号： A61K9/127 ,  A61K47/30 ,  C07H21/04 ,  C08K5/07

    CPC分类号： C07C219/14 ,  A61K9/1075 ,  C07C211/63 ,  C07C217/28 ,  C07C219/06 ,  Y10S977/797

    摘要： The present invention relates to a novel method for producing formulations comprising a polynucleotide, block copolymer and cationic surfactant. The formulations produced by the current method are suitable for use in polynucleotide based medicaments. A suitable method of production disclosed herein additionally comprises cold filtering a mixture of a polynucleotide, block copolymer and cationic surfactant, thereby sterilizing the formulation. The method of the present invention also eliminates the need for thermal cycling of the formulation, thereby reducing the time and expense required to produce large quantities of a formulation during commercial manufacturing. The present invention also relates to novel cationic lipids.

    摘要翻译： 本发明涉及一种制备包含多核苷酸，嵌段共聚物和阳离子表面活性剂的制剂的新方法。 通过当前方法制备的制剂适用于基于多核苷酸的药物。 本文公开的合适的生产方法另外包括冷过滤多核苷酸，嵌段共聚物和阳离子表面活性剂的混合物，从而对制剂灭菌。 本发明的方法也消除了对制剂的热循环的需要，从而减少在商业制造过程中生产大量制剂所需的时间和费用。 本发明还涉及新型阳离子脂质。

    Severe acute respiratory syndrome DNA compositions and methods of use
    8.
    发明授权
    Severe acute respiratory syndrome DNA compositions and methods of use 有权
    严重急性呼吸综合征DNA组成及使用方法

    公开(公告)号：US08080642B2

    公开(公告)日：2011-12-20

    申请号：US10843656

    申请日：2004-05-12

    申请人： Adrian Vilalta ,  Thomas G. Evans ,  Melanie W. Quong ,  Marston Manthorpe

    发明人： Adrian Vilalta ,  Thomas G. Evans ,  Melanie W. Quong ,  Marston Manthorpe

    IPC分类号： C07H21/02 ,  C12N15/00 ,  C12Q1/68

    CPC分类号： A61K39/215 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/70 ,  C07K14/005 ,  C12N2770/20022 ,  C12N2770/20034

    摘要： The present invention is directed to raising a detectable immune response in a vertebrate by administering in vivo, into a tissue of the vertebrate, at least one polynucleotide comprising one or more regions of nucleic acid encoding a SARS-CoV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to raising a detectable immune response in a vertebrate by administering, in vivo, into a tissue of the vertebrate, at least one SARS-CoV protein or a fragment, a variant, or derivative thereof. The SARS-CoV protein can be, for example, in purified form. The polynucleotide is incorporated into the cells of the vertebrate in vivo, and an immunologically effective amount of an immunogenic epitope of a SARS-CoV polypeptide, fragment, variant, or derivative thereof is produced in vivo. The SARS-CoV protein is also administered in an immunologically effective amount.

    摘要翻译： 本发明涉及通过在体内向脊椎动物的组织中施用至少一种包含一个或多个编码SARS-CoV蛋白或片段的核酸区域的多核苷酸来提高脊椎动物中的可检测的免疫应答，变体 ，或其衍生物。 本发明还涉及通过在体内施用脊椎动物组织，至少一种SARS-CoV蛋白或其片段，变体或衍生物来提高脊椎动物中可检测的免疫应答。 SARS-CoV蛋白可以是例如纯化形式。 将多核苷酸体内掺入脊椎动物的细胞中，在体内产生免疫有效量的SARS-CoV多肽，片段，变体或衍生物的免疫原性表位。 SARS-CoV蛋白也以免疫有效量施用。